AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ACRX is expected to report 2Q20 loss of $ 0.14 per share from revenue of $ 2.02 million.
For the full year, analysts anticipate top line of $ 17.03 million, while looking forward to loss of $ 0.53 per share bottom line.
Previous Quarter Performance
AcelRx Pharmaceuticals, Inc. recorded loss for the first quarter of $ 0.20 per share, from the revenue of $ 0.39 million. The quarterly earnings surged 23.38 percent while revenues compared with the same quarter last year.
According to street consensus, loss of $ 0.17 was expected per share The bottom line results missed street analysts by $ 0.03 or 17.65 percent, at the same time, top line results analysts by $ 22.90 million or .
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of AcelRx Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of ACRX was $ 1.32, representing a 88.57 % increase from the 52 week low of $ 0.70 and a 52.86 % decrease over the 52 week high of $ 2.80.
The company has a market capital of $ 106.61 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ACRX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
AcelRx Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.acelrx.com
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
